More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.17B
EPS
-0.9
P/E ratio
--
Price to sales
1.13
Dividend yield
--
Beta
1.555457
Previous close
$17.23
Today's open
$17.13
Day's range
$16.77 - $17.15
52 week range
$11.46 - $29.65
show more
CEO
John F. Sheridan
Employees
2650
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
69578707
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks Investment Research • Sep 17, 2026

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Zacks Investment Research • Sep 9, 2026

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Benzinga • Aug 21, 2026

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
MarketBeat • Aug 18, 2026

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
Zacks Investment Research • Aug 12, 2026

Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
MarketBeat • Aug 7, 2026

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 7, 2026

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t.
Business Wire • Aug 6, 2026

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Aug 7, 2026

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.48 per share a year ago.
Zacks Investment Research • Aug 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tandem Diabetes Care Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.